New evidence that H1N1 vaccine is linked to fetal demise.
I had been going on about this last year, such as in the video below. I hate to say that I told you so, but I told you so.
It is stated plainly in the Arepanrix adjuvanted H1N1 vaccine package that the product was associated with miscarriage, birth defects and developmental delays in rats.Nonetheless, our government continues to recommend that pregnant women take the adjuvanted vaccine if flu rates are increasing and they are unable to get the unadjuvanted version at that time. How can our public health officials consider this an acceptable risk/benefit ratio?About 1 in 450 pregnant women who catch influenza will go on to develop complications. According to data from Australian epidemiological surveillance, one in 3800 pregnant women are hospitalized for flu-related complications, but these women had other risk factors such as obesity. The risk of pregnant women dying from flu was found to be about 1/300000.
As of the making of this video on November 16, 2009, there had only been one “H1N1-related” death in a pregnant woman in Canada since the virus first appeared in April 2009, and this woman actually died of blood loss following an emergency C-section done because she was suffering respiratory distress. In other words, the flu was only very loosely connected to a single death. Meanwhile, the vaccine has to date never been tested in pregnant women and is known to have adverse outcomes in the offspring of treated rats. Clinical trials on pregnat women were SUSPENDED because the women developed fever, which is known to affect fetal development. Whether the public health officials are totally incompetent or are being negligent, either way there is a serious problem.
Arepanrix package insert stating risk of m/c, birth defects and developmental delays:
“Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute and repeated dose toxicity, local tolerance, female fertility, embryo-fetal and postnatal toxicity up to the end of the lactation period.
BUT THE DATA CONTRADICTS THE ABOVE CONCLUSION. FROM THE SAME INSERT:
“Two reproductive studies were conducted with AS03-adjuvanted H5N1 antigen and evaluated the effect on embryo-fetal and peri-and post-natal development in rats, following intramuscular administration. Although no definite conclusion could be reached, regarding a possible relation to treatment with the H5N1 vaccine and/or the adjuvant AS03, and other findings were considered normal, the following observations deserve to be mentioned: In the first study, there was an increased incidence of fetal malformations with markedly medially thickened/kinked ribs and bent scapula as well as an increased incidence of dilated ureter and delayed neurobehavioral maturation. In the second study, there was an increased incidence of post-implantation loss, and the fetal variation of dilated ureter. Not all findings were observed in both studies, and hence the toxicological significance is uncertain.”
REPORTING SUSPECTED SIDE EFFECTS
To monitor vaccine safety, the Public Health Agency of Canada collects information on serious and unexpected adverse events following vaccination. If you suspect you have had a serious or unexpected event following receipt of a vaccine you may notify the Public Health Agency of Canada:
By toll-free telephone: 1-866-844-0018
By toll-free fax: 1-866-844-5931
By email: firstname.lastname@example.org
Canadian Government dosing recommendations: